InvenireX: Revolutionizing Biotech with AI and Nanotechnology
InvenireX, a biotech company based in Newcastle Upon Tyne, UK, recently secured £500k in funding, with investors such as DSW Ventures and XTX Ventures backing the company. The purpose of this financial injection is to perfect the final prototype of their PCR laboratory tests and roll it out to external R&D laboratories for further technical validation.
Founded in 2021 by Daniel Todd, who was pursuing his PhD in DNA and nanotechnology at the University of Newcastle, InvenireX has made significant strides in developing a platform that integrates AI and programmable DNA or 'nanites'.
This innovative approach allows scientists to swiftly analyze raw material for biomarkers at very low concentrations without the need for pre-processing. The potential applications of this technology are vast, spanning from early disease detection to personalized medicine and environmental monitoring.
At present, the company is involved in two proof-of-concept studies with industry partners in the realms of agriculture and cancer detection. These collaborations aim to showcase the capabilities of InvenireX's cutting-edge solution and pave the way for broader adoption across various sectors. The future looks bright for this forward-thinking biotech firm as they continue to push the boundaries of scientific research and innovation.
They've invested in InvenireX
Get to know these Biotech investors
Click here for a full list of 7,233+ startup investors in the UK